Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Froimson Mark, holds the title of Director at Pacira BioSciences, Inc..
On 2026-11-17, the insider transacted 26,541 shares.The shares were transacted at a weighted average price of $36.50 per share, resulting in a total market-relevant value of $969K.
Froimson Mark (Director) transacted $969K of $PCRX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.